Template:Neonatal meningitis antibiotics: Difference between revisions
No edit summary |
ClaireLewis (talk | contribs) No edit summary |
||
| Line 1: | Line 1: | ||
''MRSA is uncommon in the neonate | ''[[MRSA]] is uncommon in the neonate | ||
*[[Ampicillin]] 50mg/kg IV q6hrs '''PLUS''' | *[[Ampicillin]] 50mg/kg IV q6hrs '''PLUS''' | ||
*[[Cefotaxime]] 50mg/kg IV q6hrs '''OR''' [[Gentamicin]] 2.5mg/kg IV q8hrs | *[[Cefotaxime]] 50mg/kg IV q6hrs '''OR''' [[Gentamicin]] 2.5mg/kg IV q8hrs | ||
**Per AAP, [[ceftazidime]] 50mg/kg IV (q12hr for babies < 8 days of age, q8hr for >7 days old) is a reasonable alternative to cefotaxime, offering virtually the same coverage for enteric bacilli and is FDA approved for all age groups<ref>https://www.aappublications.org/content/early/2015/02/25/aapnews.20150225-1</ref> | |||
*If suspecting [[S. pneumoniae]] or [[MRSA]], add [[Vancomycin]] | *If suspecting [[S. pneumoniae]] or [[MRSA]], add [[Vancomycin]] | ||
*Consider [[acyclovir]] for [[HSV]] | *Consider [[acyclovir]] for [[HSV]] | ||
Revision as of 00:00, 22 October 2020
MRSA is uncommon in the neonate
- Ampicillin 50mg/kg IV q6hrs PLUS
- Cefotaxime 50mg/kg IV q6hrs OR Gentamicin 2.5mg/kg IV q8hrs
- Per AAP, ceftazidime 50mg/kg IV (q12hr for babies < 8 days of age, q8hr for >7 days old) is a reasonable alternative to cefotaxime, offering virtually the same coverage for enteric bacilli and is FDA approved for all age groups[1]
- If suspecting S. pneumoniae or MRSA, add Vancomycin
- Consider acyclovir for HSV